NORGES BANK - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 244 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.

Quarter-by-quarter ownership
NORGES BANK ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q2 2024$40,100,472
+40.3%
484,715
+45.0%
0.01%
+20.0%
Q4 2023$28,590,867
+87.7%
334,357
+86.9%
0.01%
+66.7%
Q2 2023$15,230,695
-54.1%
178,890
-55.4%
0.00%
-57.1%
Q1 2023$33,162,973
-2.3%
400,761
-7.1%
0.01%
-12.5%
Q4 2022$33,931,891
+17.6%
431,429
+10.6%
0.01%0.0%
Q3 2022$28,865,037
+15.2%
389,910
+1.5%
0.01%
+33.3%
Q2 2022$25,049,000
+3.8%
384,305
+0.7%
0.01%
+20.0%
Q1 2022$24,135,563
+19.2%
381,7710.0%0.01%
+25.0%
Q4 2021$20,249,000
-25.0%
381,771
-0.2%
0.00%
-33.3%
Q3 2021$26,998,000
-18.0%
382,465
-22.6%
0.01%
-14.3%
Q2 2021$32,941,000
-31.1%
494,309
+14.8%
0.01%
-36.4%
Q1 2021$47,781,000
-20.1%
430,417
-14.5%
0.01%
-21.4%
Q4 2020$59,775,000
+32.3%
503,369
-2.8%
0.01%
+16.7%
Q3 2020$45,175,000
-15.4%
517,767
-13.2%
0.01%
-20.0%
Q2 2020$53,399,000
-25.8%
596,236
-17.4%
0.02%
-42.3%
Q1 2020$71,960,000
-13.3%
722,0590.0%0.03%
+13.0%
Q4 2019$82,965,000
-15.7%
722,059
-7.5%
0.02%
-23.3%
Q3 2019$98,456,000
+4.8%
780,5220.0%0.03%
+3.4%
Q2 2019$93,928,000
+33.6%
780,522
-2.9%
0.03%
+26.1%
Q1 2019$70,307,000
-12.6%
803,7020.0%0.02%
-23.3%
Q4 2018$80,411,000
-12.7%
803,7020.0%0.03%0.0%
Q3 2018$92,088,000
+22.1%
803,702
-4.4%
0.03%
+15.4%
Q2 2018$75,398,000
+8.1%
840,740
-11.8%
0.03%
+4.0%
Q1 2018$69,749,000
+26.0%
953,3730.0%0.02%
+25.0%
Q4 2017$55,372,000
+26.8%
953,373
-2.0%
0.02%
+17.6%
Q3 2017$43,668,000
+28.1%
973,213
+12.8%
0.02%
+21.4%
Q2 2017$34,085,000
+64.7%
863,124
+69.2%
0.01%
+75.0%
Q1 2017$20,701,000
+0.9%
510,2450.0%0.01%
-11.1%
Q4 2016$20,512,000
+58.4%
510,245
+36.3%
0.01%
+50.0%
Q3 2016$12,951,000
-4.4%
374,477
-19.9%
0.01%0.0%
Q2 2016$13,550,000
-15.3%
467,417
+2.2%
0.01%
-25.0%
Q1 2016$16,004,000
+8.5%
457,5170.0%0.01%
+14.3%
Q4 2015$14,750,000
-10.6%
457,517
-10.3%
0.01%
-22.2%
Q3 2015$16,492,000
-21.9%
510,2590.0%0.01%
-18.2%
Q2 2015$21,104,000
-7.9%
510,2590.0%0.01%0.0%
Q1 2015$22,921,000
+27.8%
510,259
+6.5%
0.01%
+22.2%
Q4 2014$17,934,000
+7.2%
479,2660.0%0.01%0.0%
Q3 2014$16,736,000
-36.2%
479,266
-35.5%
0.01%
+28.6%
Q2 2014$26,220,000
+116.5%
743,168
+100.0%
0.01%0.0%
Q1 2014$12,110,000
-22.6%
371,5840.0%0.01%
-22.2%
Q4 2013$15,655,000
+5.6%
371,5840.0%0.01%0.0%
Q3 2013$14,818,000
+57.7%
371,584
+63.5%
0.01%
+50.0%
Q2 2013$9,398,000
+27.0%
227,279
+28.0%
0.01%
+20.0%
Q1 2013$7,399,000
+3.9%
177,614
+100.0%
0.01%0.0%
Q3 2012$7,122,000
-2.8%
88,807
-12.9%
0.01%
-16.7%
Q2 2012$7,330,000101,9300.01%
Other shareholders
HAEMONETICS CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Bridge City Capital, LLC 40,541$5,114,0002.20%
Lisanti Capital Growth, LLC 53,385$6,734,0002.20%
Nitorum Capital, L.P. 279,510$35,257,0002.05%
CROWN ADVISORS MANAGEMENT, INC. 20,000$2,523,0001.69%
Millrace Asset Group, Inc. 11,400$1,438,0001.69%
COOKSON PEIRCE & CO INC 145,884$18,402,0001.61%
Endurant Capital Management LP 32,594$4,111,0001.48%
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 111,000$14,002,0001.38%
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 110,065$13,884,0001.37%
EMERALD ADVISERS, LLC 203,640$25,687,0001.20%
View complete list of HAEMONETICS CORP shareholders